"The FDA in effect serves as the re-generator of patent-protected high prices for minor drugs in each disease group, as their therapeutic equivalents lose patent protection," explains the report. "The FDA routinely approves scores of new minor variations each year, with minimal evidence about risks of harm. ... One in every five drugs approved ends up causing serious harm."